Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Arcutis Biotherapeutics (ARQT) EBIAT (2020 - 2025)

Arcutis Biotherapeutics has reported EBIAT over the past 6 years, most recently at $17.4 million for Q4 2025.

  • Quarterly results put EBIAT at $17.4 million for Q4 2025, up 261.24% from a year ago — trailing twelve months through Dec 2025 was -$16.1 million (up 88.47% YoY), and the annual figure for FY2025 was -$16.1 million, up 88.47%.
  • EBIAT for Q4 2025 was $17.4 million at Arcutis Biotherapeutics, up from $7.4 million in the prior quarter.
  • Over the last five years, EBIAT for ARQT hit a ceiling of $17.4 million in Q4 2025 and a floor of -$107.7 million in Q3 2022.
  • Median EBIAT over the past 5 years was -$48.5 million (2023), compared with a mean of -$46.8 million.
  • Biggest five-year swings in EBIAT: tumbled 109.48% in 2021 and later surged 261.24% in 2025.
  • Arcutis Biotherapeutics' EBIAT stood at -$71.3 million in 2021, then fell by 0.97% to -$72.0 million in 2022, then increased by 7.96% to -$66.3 million in 2023, then skyrocketed by 83.72% to -$10.8 million in 2024, then surged by 261.24% to $17.4 million in 2025.
  • The last three reported values for EBIAT were $17.4 million (Q4 2025), $7.4 million (Q3 2025), and -$15.9 million (Q2 2025) per Business Quant data.